Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients

Cristina Raimondi, Angela Gradilone, Giuseppe Naso, Bruno Vincenzi, Arianna Petracca, Chiara Nicolazzo, Antonella Palazzo, Rosa Saltarelli, Franco Spremberg, Enrico Cortesi, Paola Gazzaniga

Research output: Contribution to journalArticle

187 Citations (Scopus)

Abstract

Currently used methods to detect and enumerate circulating tumor cells (CTCs) rely on the expression of the epithelial cell adhesion molecule (EpCAM) and cytokeratins. This selection may exclude cells that have undergone intrinsic modifications of their phenotype, as epithelialmesenchymal transition (EMT). Aim of the study was to investigate the expression of EMT and stemness markers in CTCs from breast cancer patients in all stages of disease. 92 female breast cancer patients were enrolled. CTCs were isolated by CELLection TM Dynabeads® coated with the monoclonal antibody toward EpCam. Samples found positive for CTCs presence (CD45-/CK?) were evaluated for the expression of ER alpha, HER2, ALDH1, vimentin, and fibronectin. Samples negative for CTCs presence (CD45-/CK-) were also evaluated for the expression of vimentin and fibronectin, used as markers of EMT. CTCs were found in 66% of patients. The distribution of CTCs presence according to stage and grade of disease was found statistically significant. The expression of ALDH1 on CTCs was found to correlate to stage of disease and to the expression of vimentin and fibronectin. In 34% of patients, we detected cells with negative CK/CD45 expression but positive expression of vimentin and fibronectin. There is an urgent need for optimizing CTCs detection methods through the inclusion of EMT markers. The detection of cells in mesenchymal transition, retaining EMT and stemness features, may contribute to discover additional therapeutic targets useful to eradicate micrometastatic disease in breast cancer.

Original languageEnglish
Pages (from-to)449-455
Number of pages7
JournalBreast Cancer Research and Treatment
Volume130
Issue number2
DOIs
Publication statusPublished - Nov 2011

Fingerprint

Circulating Neoplastic Cells
Epithelial-Mesenchymal Transition
Breast Neoplasms
Vimentin
Fibronectins
Keratins
Monoclonal Antibodies
Phenotype

Keywords

  • Cancer stem cells
  • Circulating tumor cells
  • Cytokeratins
  • Epithelial-mesenchymal transition

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Raimondi, C., Gradilone, A., Naso, G., Vincenzi, B., Petracca, A., Nicolazzo, C., ... Gazzaniga, P. (2011). Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients. Breast Cancer Research and Treatment, 130(2), 449-455. https://doi.org/10.1007/s10549-011-1373-x

Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients. / Raimondi, Cristina; Gradilone, Angela; Naso, Giuseppe; Vincenzi, Bruno; Petracca, Arianna; Nicolazzo, Chiara; Palazzo, Antonella; Saltarelli, Rosa; Spremberg, Franco; Cortesi, Enrico; Gazzaniga, Paola.

In: Breast Cancer Research and Treatment, Vol. 130, No. 2, 11.2011, p. 449-455.

Research output: Contribution to journalArticle

Raimondi, C, Gradilone, A, Naso, G, Vincenzi, B, Petracca, A, Nicolazzo, C, Palazzo, A, Saltarelli, R, Spremberg, F, Cortesi, E & Gazzaniga, P 2011, 'Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients', Breast Cancer Research and Treatment, vol. 130, no. 2, pp. 449-455. https://doi.org/10.1007/s10549-011-1373-x
Raimondi, Cristina ; Gradilone, Angela ; Naso, Giuseppe ; Vincenzi, Bruno ; Petracca, Arianna ; Nicolazzo, Chiara ; Palazzo, Antonella ; Saltarelli, Rosa ; Spremberg, Franco ; Cortesi, Enrico ; Gazzaniga, Paola. / Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients. In: Breast Cancer Research and Treatment. 2011 ; Vol. 130, No. 2. pp. 449-455.
@article{ee4928ce890443af976b73c091958dd4,
title = "Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients",
abstract = "Currently used methods to detect and enumerate circulating tumor cells (CTCs) rely on the expression of the epithelial cell adhesion molecule (EpCAM) and cytokeratins. This selection may exclude cells that have undergone intrinsic modifications of their phenotype, as epithelialmesenchymal transition (EMT). Aim of the study was to investigate the expression of EMT and stemness markers in CTCs from breast cancer patients in all stages of disease. 92 female breast cancer patients were enrolled. CTCs were isolated by CELLection TM Dynabeads{\circledR} coated with the monoclonal antibody toward EpCam. Samples found positive for CTCs presence (CD45-/CK?) were evaluated for the expression of ER alpha, HER2, ALDH1, vimentin, and fibronectin. Samples negative for CTCs presence (CD45-/CK-) were also evaluated for the expression of vimentin and fibronectin, used as markers of EMT. CTCs were found in 66{\%} of patients. The distribution of CTCs presence according to stage and grade of disease was found statistically significant. The expression of ALDH1 on CTCs was found to correlate to stage of disease and to the expression of vimentin and fibronectin. In 34{\%} of patients, we detected cells with negative CK/CD45 expression but positive expression of vimentin and fibronectin. There is an urgent need for optimizing CTCs detection methods through the inclusion of EMT markers. The detection of cells in mesenchymal transition, retaining EMT and stemness features, may contribute to discover additional therapeutic targets useful to eradicate micrometastatic disease in breast cancer.",
keywords = "Cancer stem cells, Circulating tumor cells, Cytokeratins, Epithelial-mesenchymal transition",
author = "Cristina Raimondi and Angela Gradilone and Giuseppe Naso and Bruno Vincenzi and Arianna Petracca and Chiara Nicolazzo and Antonella Palazzo and Rosa Saltarelli and Franco Spremberg and Enrico Cortesi and Paola Gazzaniga",
year = "2011",
month = "11",
doi = "10.1007/s10549-011-1373-x",
language = "English",
volume = "130",
pages = "449--455",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York LLC",
number = "2",

}

TY - JOUR

T1 - Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients

AU - Raimondi, Cristina

AU - Gradilone, Angela

AU - Naso, Giuseppe

AU - Vincenzi, Bruno

AU - Petracca, Arianna

AU - Nicolazzo, Chiara

AU - Palazzo, Antonella

AU - Saltarelli, Rosa

AU - Spremberg, Franco

AU - Cortesi, Enrico

AU - Gazzaniga, Paola

PY - 2011/11

Y1 - 2011/11

N2 - Currently used methods to detect and enumerate circulating tumor cells (CTCs) rely on the expression of the epithelial cell adhesion molecule (EpCAM) and cytokeratins. This selection may exclude cells that have undergone intrinsic modifications of their phenotype, as epithelialmesenchymal transition (EMT). Aim of the study was to investigate the expression of EMT and stemness markers in CTCs from breast cancer patients in all stages of disease. 92 female breast cancer patients were enrolled. CTCs were isolated by CELLection TM Dynabeads® coated with the monoclonal antibody toward EpCam. Samples found positive for CTCs presence (CD45-/CK?) were evaluated for the expression of ER alpha, HER2, ALDH1, vimentin, and fibronectin. Samples negative for CTCs presence (CD45-/CK-) were also evaluated for the expression of vimentin and fibronectin, used as markers of EMT. CTCs were found in 66% of patients. The distribution of CTCs presence according to stage and grade of disease was found statistically significant. The expression of ALDH1 on CTCs was found to correlate to stage of disease and to the expression of vimentin and fibronectin. In 34% of patients, we detected cells with negative CK/CD45 expression but positive expression of vimentin and fibronectin. There is an urgent need for optimizing CTCs detection methods through the inclusion of EMT markers. The detection of cells in mesenchymal transition, retaining EMT and stemness features, may contribute to discover additional therapeutic targets useful to eradicate micrometastatic disease in breast cancer.

AB - Currently used methods to detect and enumerate circulating tumor cells (CTCs) rely on the expression of the epithelial cell adhesion molecule (EpCAM) and cytokeratins. This selection may exclude cells that have undergone intrinsic modifications of their phenotype, as epithelialmesenchymal transition (EMT). Aim of the study was to investigate the expression of EMT and stemness markers in CTCs from breast cancer patients in all stages of disease. 92 female breast cancer patients were enrolled. CTCs were isolated by CELLection TM Dynabeads® coated with the monoclonal antibody toward EpCam. Samples found positive for CTCs presence (CD45-/CK?) were evaluated for the expression of ER alpha, HER2, ALDH1, vimentin, and fibronectin. Samples negative for CTCs presence (CD45-/CK-) were also evaluated for the expression of vimentin and fibronectin, used as markers of EMT. CTCs were found in 66% of patients. The distribution of CTCs presence according to stage and grade of disease was found statistically significant. The expression of ALDH1 on CTCs was found to correlate to stage of disease and to the expression of vimentin and fibronectin. In 34% of patients, we detected cells with negative CK/CD45 expression but positive expression of vimentin and fibronectin. There is an urgent need for optimizing CTCs detection methods through the inclusion of EMT markers. The detection of cells in mesenchymal transition, retaining EMT and stemness features, may contribute to discover additional therapeutic targets useful to eradicate micrometastatic disease in breast cancer.

KW - Cancer stem cells

KW - Circulating tumor cells

KW - Cytokeratins

KW - Epithelial-mesenchymal transition

UR - http://www.scopus.com/inward/record.url?scp=82955187028&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82955187028&partnerID=8YFLogxK

U2 - 10.1007/s10549-011-1373-x

DO - 10.1007/s10549-011-1373-x

M3 - Article

VL - 130

SP - 449

EP - 455

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 2

ER -